XML 68 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Revenues by Product
Product revenues, net consisted of the following:
202220212020
(in millions)
TRIKAFTA/KAFTRIO$7,686.8 $5,697.2 $3,863.8 
SYMDEKO/SYMKEVI180.0 420.4 628.6 
ORKAMBI510.7 771.6 907.5 
KALYDECO553.2 684.2 802.9 
Total product revenues, net$8,930.7 $7,573.4 $6,202.8 
Revenues and Property and Equipment by Location
Net product revenues are attributed to countries based on the location of the customer and consisted of the following:
202220212020
(in millions)
United States$5,699.3 $5,287.3 $4,826.4 
Outside of the United States
Europe2,705.5 1,972.9 1,126.5 
Other
525.9 313.2 249.9 
Total product revenues outside of the United States
3,231.4 2,286.1 1,376.4 
Total product revenues, net
$8,930.7 $7,573.4 $6,202.8 
Long-lived assets by location consisted of the following:
As of December 31,
20222021
(in millions)
United States$1,365.5 $1,348.1 
Outside of the United States
United Kingdom75.7 60.9 
Other14.6 15.4 
Total long-lived assets outside of the United States90.3 76.3 
Total long-lived assets$1,455.8 $1,424.4 
Significant Customers
Gross product revenues and accounts receivable from each of our customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:
Percent of
Total Gross Product Revenues
Percent of
Accounts Receivable
Year Ended December 31,
As of December 31,
20222021202020222021
McKesson Corporation25 %22 %20 %22 %21 %
Accredo Health Group, Inc.12 %12 %15 %<10%10 %
Walgreen Co.10 %10 %14 %<10%<10 %
Lloyds Pharmacy*<10%<10%<10%12 %15 %
*A wholly-owned subsidiary of McKesson Corporation in the U.K. until 2022.